RSS-Feed abonnieren
DOI: 10.1055/s-2008-1027323
© Georg Thieme Verlag KG Stuttgart · New York
Dilemmas in Therapy of Gestational Breast Cancer: Review of Literature
Dilemma in der Therapie bei Schwangeren mit Brustkrebs: Übersicht der LiteraturPublikationsverlauf
Publikationsdatum:
18. April 2008 (online)

Zusammenfassung
Gegenstand: Unter Verwendung von meist rückblickenden/retrospektiven Studien und diverser anderer verfügbarer Publikationen ist das Ziel dieser Besprechung/dieses Reviews aufzuzeigen, dass es neben den meisten geklärten Problemen noch verschiedene Unklarheiten bezüglich der GBC-Behandlung (Behandlung von Brustkrebs in der Schwangerschaft) gibt. Ergebnisse: Die Mehrheit der verwendeten Publikationen stellen klare Positionen im Hinblick auf die chirurgische Behandlung von GBC dar, wobei eine modifizierte radikale Brustamputation in diesen Präsentationen vorherrscht - unabhängig vom Stadium der Krankheit oder der Schwangerschaft. Aber es gibt Möglichkeiten der Anwendung von brusterhaltenden Eingriffen in Fällen mit einem geringeren Erkrankungsstadium, wenn postoperative Bestrahlung angewendet wird. Soweit die Strahlentherapie bei GBC angewendet wird, hat die Mehrheit der Autorenprotokolle ein klares Verständnis über die Risiken, die die Bestrahlung für den Fötus mit sich bringt und wie das Risiko im Hinblick auf das Stadium der Schwangerschaft bzw. im Hinblick auf die Entwicklung des Fötus zu analysieren ist. Zweifellos sind im ersten Trimester, während der Einnistung in den ersten zehn Tagen und während der Entwicklung der Organe, die zerstörenden Effekte der Bestrahlung am höchsten. Der Erfolg und die eingesetzten Modelle bei der Chemotherapie gegen GBC sind ebenso abhängig vom Stadium der Schwangerschaft. In allen Publikationen ist klar herausgestellt, dass die Chemotherapie im ersten Trimester der Schwangerschaft wegen allen neuro- und kardiotoxischen Effekten und der beträchtlichen Verzögerung des Wachstums des Fötus nicht akzeptabel ist. Wenn die Chemotherapie im dritten Trimester benötigt wird, kann sie auf den Zeitpunkt nach der Entbindung verzögert werden. Es besteht heutzutage Konsens dahingehend, dass der therapeutische Abort vermieden werden sollte - außer in klar definierten Fällen von GBC. Zusammenfassung: Das größte Problem im Hinblick auf die Festlegung der multidisziplinären Behandlung von GBC ist die kleine Anzahl von vorausblickenden/prospektiven Studien, während retrospektive Studien auf lange zeitliche Perioden der Beobachtung nach der Behandlung von GBC sowie der Behandlung durch mehrere Ärzte und der Verwendung von manchmal verschiedenen Behandlungsansätzen basieren. Es bleibt zu sagen, dass die Literatur heutzutage zeigt, dass das Stadium der Schwangerschaft bzw. das Alter des Fetus das grundlegende Kriterium für jegliche Art von Behandlung von GBC ist.
Abstract
Purpose: Goal of this review is, by using data of mostly retrospective studies and other available publications, to point out that besides most of cleared problems, there are several dilemmas in GBC treatment. Patients and methods: Reviewing protocols using Medline database as well as conclusions from meetings specialized on this topic, we found that greatest problems are in chemotherapy and irradiation of patients in I. and II. trimester. Problems in surgical part of treatment are considerably smaller. Results: Majority of used publications bring us clear positions about surgical treatment of GBC where modified radical mastectomy is prevailing, regardless to stage of disease or pregnancy. But, there are possibilities for usage of breast conserving surgery in cases with lower grade of the disease, if postoperative irradiation is used. As far as radiotherapy of GBC is used, majority of protocols consider clear understanding of risks that radiation carries for the fetus, and how the risk is to be analyzed considering stage of pregnancy, or in other words, stage of fetal development. Without doubt, highest level of deletory effects of radiation is in first trimester, during implantation in first ten days, and after, during organogenesis. Success and models used in chemotherapy in GBC is also dependable on stage of the pregnancy. All publications state clearly that chemotherapy is not acceptable in first trimester of pregnancy, due to all neuro and cardio toxic effects and considerable growth retardation. If needed during third trimester, chemotherapy can be delayed after delivery. There is consensus today that therapeutic abortion is to be avoided, except clearly defined cases of GBC. Conclusion: Biggest problem in getting the multidisciplinary treatment of GBC more clear is small number of prospective studies, while retrospective studies are based on tracking the patients after long periods after the treatment of GBC as well as patients treated by several physicians and using sometimes different approaches. It still remains to be said, literature shows today that stage of pregnancy, or in other words, age of fetus, is base criteria for any kind of treatment of GBC.
Schlüsselwörter
Schwangerschaftsbrustkrebs - therapeutische Schwierigkeiten/Dilemma - Literaturangaben
Key words
gestational breast cancer - dilemmas in therapy - review of literature
References
- 1
Nugent P, O’Connell T X.
Breast cancer and pregnancy.
Arch Surg.
1985;
120
1221-1224
Reference Ris Wihthout Link
- 2
Applewhite R R, Smith L R, De Vincenti F.
Carcinoma of the breast associated with pregnancy and lactation.
Am Surg.
1973;
39
101-104
Reference Ris Wihthout Link
- 3
Treves N, Holleb A I.
report of 549 cases of breast cancer in women 35 years of age or younger.
Gynecol Obstet.
1958;
107
271
Reference Ris Wihthout Link
- 4
Bauerfeind I, Lenhard M, Kahlert S. et al .
Review: breast cancer and pregnancy.
Eur Clin Obste & Gynec.
2005;
1 (No 2)
95-101
Reference Ris Wihthout Link
- 5
Merviel P, Salat-Baroux J, Uzan S.
Cancer du sein au cours dela grossesse.
Bull Cancer.
1996;
83
266-175
Reference Ris Wihthout Link
- 6
Haagensen C D, Stout A P.
Carcinoma of the breast. Criteria for operability.
Ann Surg.
1943;
118
859-870
Reference Ris Wihthout Link
- 7
Epstein R J.
Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard
of care.
MBC Cancer.
2007;
7
92
Reference Ris Wihthout Link
- 8
Molckovsky A, Madarnas Y.
Breast cancer in pregnancy: a literature review.
Breast Cancer Res Treat.
2007;
(Epub ahead of print)
Reference Ris Wihthout Link
- 9
Partridge A H, Lesnikoski B A, Burstein H J.
Treatment of breast cancer during pregnancy. Summary Expert Opinion on Pharmacotherapy.
Expert Opinion.
2002;
3 (4)
423-428
Reference Ris Wihthout Link
- 10
Puckridge P J, Saunders C M, Ives A D. et al .
Breast cancer and pregnancy: A diagnostic and management dilemma.
ANZ J Surg.
2003;
73
500-503
Reference Ris Wihthout Link
- 11
Saunders C, Hickey M, Ives A.
Breast Cancer During Pregnancy.
Int J Fertil.
2004;
49 (5)
1-5
Reference Ris Wihthout Link
- 12
Gemignani M L, Petrek J A, Borgen P I.
Breast cancer and pregnancy.
Surg Clin North Am.
1999;
79
1157-1169
Reference Ris Wihthout Link
- 13 Fajdić J. Rak dojke tijekom trudnoće i dojenja. U: Deveti znanstveni sastanak bolesti dojke, Zbornik radova Zagreb; HAZU 1999: 55-65
Reference Ris Wihthout Link
- 14
Melnick D M, Wahl W L, Dalton V K.
Management of general surgical problems in the pregnant patient.
Am J Surg.
2004;
187
170-180
Reference Ris Wihthout Link
- 15
Hoover H.
Breast cancer during pregnancy and lactation.
Surg Clin North Am.
1990;
70
1151-1163
Reference Ris Wihthout Link
- 16
Kuerer H M, Gwyn K, Ames F C. et al .
Conservative surgery and chemotherapy for breast carcinoma during pregnancy.
Surgery.
2002;
131
108-110
Reference Ris Wihthout Link
- 17
Psyrri A, Burtness B.
Pregnancy-Associated Breast cancer.
Cancer J.
2005;
11
83-95
Reference Ris Wihthout Link
- 18
Keleher A J, Theriault R L, Gwyn K M. et al .
Multidisciplinary management of breast cancer concurrent with pregnancy.
J Am Coll Surg.
2001;
194
54-64
Reference Ris Wihthout Link
- 19
Gwyn K, Theriault R.
Breast cancer during pregnancy.
Oncology.
2001;
15
39-46
Reference Ris Wihthout Link
- 20
D’Ercole F J, Scott D, Bell E. et al .
Paravertebral blockade for modified radical mastectomy in a pregnant patient.
Anesth Analg.
1999;
88
1351-1353
Reference Ris Wihthout Link
- 21
Mazze R I, Kallen B.
Reproductive outcome after anesthesia and operation during pregnancy: a registry study
of 5405 cases.
Am J Obstet Gynecol.
1989;
161
1178-1185
Reference Ris Wihthout Link
- 22
Petrek J A.
Breast cancer during pregnancy.
Cancer.
1994;
74
518-527
Reference Ris Wihthout Link
- 23
Hill M A, Albert T, Zieske A. et al .
Successful resection of multifocal hepatic adenoma during pregnancy.
South Med J.
1997;
90
357-361
Reference Ris Wihthout Link
- 24
Terkivatan T, De Wilt J HW, deMan R A. et al .
Management of hepatocellular adenoma during pregnancy.
Liver.
2000;
20
186-187
Reference Ris Wihthout Link
- 25
Brunt L M.
Phaeochromocytoma in pregnancy.
Br J Surg.
2001;
88
481-483
Reference Ris Wihthout Link
- 26
Dave S P, Reis E D, Hossain A. et al .
Splenic artery aneurysm in the 1990s.
Ann Vasc Surg.
2000;
14
223-229
Reference Ris Wihthout Link
- 27
Caillouette J C, Merchant E B.
Ruptured splenic artery aneurysm in pregnancy: twelfth reported case with maternal
and fetal survival.
Am J Obstet Gynecol.
1993;
168
1810-1813
Reference Ris Wihthout Link
- 28
Saunders C M, Baum M.
Breast cancer and pregnancy: a review.
J R Soc Med.
1993;
86
162-165
Reference Ris Wihthout Link
- 29
Doll D C, Ringeberg Q S, Yarbro J W.
Management of cancer during pregnancy.
Arch Intern Med.
1988;
148
2058-2064
Reference Ris Wihthout Link
- 30
Hubay C A, Barry F M, Marr C C.
Pregnancy and breast cancer.
Surg Clin North Am.
1978;
58
819-831
Reference Ris Wihthout Link
- 31
Jablon S, Kato H.
Childhood cancer in relation to prenatal exposure to atomic-bomb radiation.
Lancet.
1970;
2
1000-1003
Reference Ris Wihthout Link
- 32
MacMahon B.
Prenatal x-ray exposure and childhood cancer.
J Natl Cancer Inst.
1962;
28
1173-1191
Reference Ris Wihthout Link
- 33
Gustavson K H, Jagell S, Blomquist H K. et al .
Microcephaly mental retardation and chromosomal aberrations in a girl following radiation
therapy during late fetal life.
Acta Radiol Oncol.
1981;
20
209-212
Reference Ris Wihthout Link
- 34
Bloom A D, Neriishi S, Kamada N. et al .
Cytogenetic investigation of survivors of the atomic bombings of Hiroshima and Nagasaki.
Lancet.
1966;
2
672-674
Reference Ris Wihthout Link
- 35
Stewart A, Kneale G W.
Radiation dose effects in relation to obstetric x-rays and childhood cancers.
Lancet.
1970;
1
1185-1188
Reference Ris Wihthout Link
- 36
Court-Brown W M, Doll R, Hill R B.
Incidence of leukemia after exposure to diagnostic radiation in utero.
Br Med J.
1960;
2
1539-1545
Reference Ris Wihthout Link
- 37
Ricoul M, Dutrillaux B.
Chromosome hyper-radiosensitivity in mice at the end of pregnancy.
C R Acad Sci III.
1991;
312
635-639
Reference Ris Wihthout Link
- 38
Wood J W, Johnson K G, Omori Y. et al .
mental retardation in children exposed in utero to the atomic bombs in Hiroshima and
Nagasaki.
A J Public Health Nations Health.
1967;
57
1381-1389
Reference Ris Wihthout Link
- 39
Otake M, Schull W J.
In utero exposure to A-bomb radiation and mental retardation: a reassessment.
Br J Radiol.
1984;
57
409-414
Reference Ris Wihthout Link
- 40
Tabuchi A, Nakagawa S, Hirai T. et al .
Fetal hazards due to x-ray diagnosis during pregnancy.
Hiroshima J Med Sci.
1967;
16
49-66
Reference Ris Wihthout Link
- 41
Van der Vange N, Dongen van J.
Breast cancer and pregnancy.
Eur J Surg Oncol.
1991;
17
1-8
Reference Ris Wihthout Link
- 42
Tralins A H.
Lactation after conservative breast surgery combined with radiation therapy.
Am J Clin Oncol.
1995;
18
40-43
Reference Ris Wihthout Link
- 43
Doll D C, Ringenberg Q S, Yarbro J W.
Antineoplastic agents and pregnancy.
Semin Oncol.
1989;
16
337-346
Reference Ris Wihthout Link
- 44
Bawle E V, Conard J V, Weiss L.
Adult and two children with fetal methotrexate syndrome.
Teratology.
1998;
57
51-55
Reference Ris Wihthout Link
- 45
Ebert U, Loffler H, Kirch W.
Cytotoxic therapy and pregnancy.
Pharmacol Ther.
1997;
74
207-220
Reference Ris Wihthout Link
- 46
Nagai H.
Effects of transplacentally injected alkylating agents upon development of embryos:
appearance of intrauterine death and mesodermal malformation.
Bull Tokyo Dent Coll.
1972;
13
103-119
Reference Ris Wihthout Link
- 47
Nettleton J, Long J, Kuban D. et al .
Breast cancer during pregnancy: quantifying the risk of treatment delay.
Obstet Gynecol.
1996;
87
414-418
Reference Ris Wihthout Link
- 48
Berry D L, Theriault R L, Holmes F A. et al .
Management of breast cancer during pregnancy using a standardized protocol.
J Clin Oncol.
1999;
17
855-861
Reference Ris Wihthout Link
- 49
Giacalone P L, Laffargue F, Benos P.
Chemotherapy for breast carcinoma during pregnancy: a French national survey.
Cancer.
1999;
86
2266-2272
Reference Ris Wihthout Link
- 50
Reynoso E E, Shepherd F A, Messner H A. et al .
Acute leukemia during pregnancy: the Toronto leukemia Study Group experience with
long-term follow-up of children exposed in utero to chemotherapeutic agents.
J Clin Oncol.
1987;
5
1098-1106
Reference Ris Wihthout Link
- 51
Garber J E.
Long-term follow-up of the children exposed in utero to antineoplastic agents.
Seminars Oncol.
1989;
16
437-444
Reference Ris Wihthout Link
- 52
Ebert U, Lofller H, Kirch W.
Cytotoxic therapy anda pregnancy.
Pharmacol Ther.
1997;
74
207-220
Reference Ris Wihthout Link
- 53
Nicholson H O.
Leukemia and pregnancy. A report of five cases and discussion of management.
J Obstet Gynecol Br Commonw.
1968;
75
517-520
Reference Ris Wihthout Link
- 54
Williams S F, Schilsky R L.
Antineoplastic drugs administered during pregnancy.
Semin Oncol.
2000;
27
618-622
Reference Ris Wihthout Link
- 55
Barthelmes L, Davidson L A, Gaffney C. et al .
Pregnancy and breast cancer.
BMJ.
2005;
330
1375-1378
Reference Ris Wihthout Link
- 56
Moore H CF, Foster R S.
Breast cancer and pregnancy.
Semin Oncol.
2000;
27
646-653
Reference Ris Wihthout Link
- 57
Clark R M, Reid J.
Carcinoma of the breast in pregnancy or lactation.
Int J Radiat Oncol Biol Phys.
1978;
4
693-698
Reference Ris Wihthout Link
- 58
Clark R, Chua T.
Breast cancer and pregnancy: The ultimate challange.
Clin Oncol.
1989;
1
11-18
Reference Ris Wihthout Link
Z. Hrgovic, MD, PhD
Kaiserstraße 15
60311 Frankfurt
Germany
Telefon: ++ 49/69/29 30 00
Fax: ++ 49/69/29 16 97
eMail: info@hrgovic.de